Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD
U.S. Bancorp (USB): Vice Chairman and CFO Andrew Cecere Sold 259,355 Shares
Vice Chairman and CFO Andrew Cecere sold 259,355 shares of USB stock on July 18 at the average price of $37.02. Andrew Cecere owns at least 238,032 shares after this. The price of the stock has increased by 0.65% since.
U.S. Bancorp was incorporated in Delaware in 1929. It is a multi-state financial services holding company headquartered in Minneapolis, Minnesota. U.S. Bancorp has a market cap of $68.57 billion; its shares were traded at around $37.26 with a P/E ratio of 12.87 and P/S ratio of 3.51. The dividend yield of U.S. Bancorp stocks is 2.19%. U.S. Bancorp had an annual average earnings growth of 19.6% over the past 5 years.
U.S. Bancorp released its second quarter 2013 results on July 17, 2013. For this quarter, the company reported net income of $1.48 billion ($0.76 per diluted share). The company's annual dividend was raised from $0.78 to $0.92, return on average assets was 1.7%, and return on average common equity was 16.1%.
Chairman, President and CEO Richard K Davis sold 286,900 shares of USB stock on July 19 at the average price of $37.27. Vice Chairman Pamela A Joseph and multiple other insiders all also sold shares of USB stock over the past week.
Seattle Genetics Inc. (SGEN): CFO Todd E Simpson Sold 92,527 Shares
CFO Todd E Simpson sold 92,527 shares of SGEN stock on July 12 at the average price of $37.45. Todd Simpson owns at least 113,957 shares after this. The price of the stock has increased by 4.43% since.
Seattle Genetics, Inc. was incorporated in Delaware on July 15, 1997. Seattle Genetics, Inc. has a market cap of $4.72 billion; its shares were traded at around $39.11 with and P/S ratio of 21.14.
Seattle Genetics reported first quarter 2013 results ended March 31, 2013. Total revenues for the quarter were $57.3 million compared to $48.2 million prior year quarter. Net loss was $16.3 million ($0.14 per share), compared to a loss of $12.3 million ($0.11 per share) last year.
Cardinal Health Inc (CAH): CFO Jeffrey William Henderson Sold 97,871 Shares
CFO of Cardinal Health Inc (CAH) Jeffrey William Henderson sold 97,871 shares during the past week at an average price of $48.99.
Cardinal Health, Inc is an Ohio corporation formed in 1979. Cardinal Health Inc has a market cap of $17.15 billion; its shares were traded at around $50.52 with a P/E ratio of 15.08 and P/S ratio of 0.17. The dividend yield of Cardinal Health Inc stocks is 2.16%.
Cardinal Health Inc. reported second quarter 2013 revenues of $24.6 billion, with a 28% increase in non-GAAP earnings per share to $1.20. GAAP EPS from continuing operations increased 5% to $1.00.
Alexion Pharmaceuticals, Inc. (ALXN): EVP & CFO Vikas Sinha Sold 50,000 Shares
EVP & CFO Vikas Sinha sold 50,000 shares of ALXN stock on July 12 at the average price of $120. Vikas Sinha owns at least 312,655 shares after this. The price of the stock has decreased by 6.53% since.
Alexion Pharmaceuticals Inc. is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals Inc. has a market cap of $21.77 billion; its shares were traded at around $112.17 with a P/E ratio of 76.92 and P/S ratio of 18.21. Alexion Pharmaceuticals Inc. had an annual average earnings growth of 70.6% over the past 5 years.
Alexion Pharmaceuticals Inc. has released its first quarter 2013 results. First quarter net product sales increased 38% to $338.9 million. GAAP net income grew 81% to $82.2 million ($0.41 per share), with non-GAAP income growing 49% to $131.1 million.
EVP Chief Commercial Officer David Hallal, and EVP Chief Global Ops. Officer Stephen P Squinto both also sold shares of ALXN stock on July 12.
CFO Robert Bowen sold 40,786 shares of ABMD stock on July 15 at the average price of $23.5. Robert Bowen owns at least 66,929 shares after this. The price of the stock has increased by 4.04% since.
Abiomed Inc. was incorporated in Delaware. The Company is a provider of mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. Abiomed Inc. has a market cap of $949.945 million; its shares were traded at around $24.45 with a P/E ratio of 66.23 and P/S ratio of 6.36.
Abiomed Inc. has released its fourth quarter 2013 results. The company increased revenue by 17% to $43.7 million. GAAP net income was $3.7 million ($0.09 per diluted share), compared to income of $2.6 million ($0.06 per share) prior year quarter.
For the complete list of stocks that Sold by their CFOs, go to: Insider Buys.